Does the media prefer SNWV or NMTC?

In the previous week, NeuroOne Medical Technologies had 8 more articles in the media than Sanuwave Health. MarketBeat recorded 11 mentions for NeuroOne Medical Technologies and 3 mentions for Sanuwave Health. NeuroOne Medical Technologies' average media sentiment score of 0.70 beat Sanuwave Health's score of 0.00 indicating that NeuroOne Medical Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanuwave Health 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NeuroOne Medical Technologies 2 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BEAT or NMTC?

In the previous week, NeuroOne Medical Technologies had 2 more articles in the media than HeartBeam. MarketBeat recorded 11 mentions for NeuroOne Medical Technologies and 9 mentions for HeartBeam. NeuroOne Medical Technologies' average media sentiment score of 0.70 beat HeartBeam's score of 0.10 indicating that NeuroOne Medical Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HeartBeam 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral NeuroOne Medical Technologies 2 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NMTC or ELUT?

In the previous week, NeuroOne Medical Technologies had 9 more articles in the media than Elutia. MarketBeat recorded 11 mentions for NeuroOne Medical Technologies and 2 mentions for Elutia. NeuroOne Medical Technologies' average media sentiment score of 0.70 beat Elutia's score of 0.00 indicating that NeuroOne Medical Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroOne Medical Technologies 2 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elutia 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ARAY or NMTC?

In the previous week, NeuroOne Medical Technologies had 6 more articles in the media than Accuray. MarketBeat recorded 11 mentions for NeuroOne Medical Technologies and 5 mentions for Accuray. NeuroOne Medical Technologies' average media sentiment score of 0.70 beat Accuray's score of 0.55 indicating that NeuroOne Medical Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Accuray 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NeuroOne Medical Technologies 2 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NMTC or QTI?

In the previous week, NeuroOne Medical Technologies had 7 more articles in the media than QT Imaging. MarketBeat recorded 11 mentions for NeuroOne Medical Technologies and 4 mentions for QT Imaging. NeuroOne Medical Technologies' average media sentiment score of 0.70 beat QT Imaging's score of 0.66 indicating that NeuroOne Medical Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroOne Medical Technologies 2 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive QT Imaging 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

NeuroOne Medical Technologies (NMTC) Competitors

$1.12 +0.04 (+3.70%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.12 +0.00 (+0.18%)

As of 10/9/2026 07:30 PM Eastern

Compare

NMTC vs. SNWV, BEAT, ELUT, ARAY, and QTI

Should you buy NeuroOne Medical Technologies stock or one of its competitors? NeuroOne Medical Technologies's main competitors and comparable companies include Sanuwave Health (SNWV), HeartBeam (BEAT), Elutia (ELUT), Accuray (ARAY), and QT Imaging (QTI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does NeuroOne Medical Technologies compare to Sanuwave Health?

Sanuwave Health (NASDAQ:SNWV) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

In the previous week, NeuroOne Medical Technologies had 8 more articles in the media than Sanuwave Health. MarketBeat recorded 11 mentions for NeuroOne Medical Technologies and 3 mentions for Sanuwave Health. NeuroOne Medical Technologies' average media sentiment score of 0.70 beat Sanuwave Health's score of 0.00 indicating that NeuroOne Medical Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanuwave Health	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NeuroOne Medical Technologies	2 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

42.5% of Sanuwave Health shares are owned by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. 14.4% of Sanuwave Health shares are owned by company insiders. Comparatively, 11.8% of NeuroOne Medical Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Sanuwave Health has a net margin of 32.38% compared to NeuroOne Medical Technologies' net margin of -71.50%. Sanuwave Health's return on equity of 1,728.10% beat NeuroOne Medical Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanuwave Health	32.38%	1,728.10%	39.04%
NeuroOne Medical Technologies	-71.50%	-128.12%	-86.34%

Sanuwave Health currently has a consensus target price of $47.00, indicating a potential upside of 736.30%. NeuroOne Medical Technologies has a consensus target price of $7.33, indicating a potential upside of 554.76%. Given Sanuwave Health's higher probable upside, equities analysts plainly believe Sanuwave Health is more favorable than NeuroOne Medical Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanuwave Health	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
NeuroOne Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Sanuwave Health has higher revenue and earnings than NeuroOne Medical Technologies. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Sanuwave Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanuwave Health	$44.02M	1.10	$11.81M	$0.24	23.42
NeuroOne Medical Technologies	$12.10M	0.84	-$3.61M	-$0.95	N/A

Sanuwave Health has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market. Comparatively, NeuroOne Medical Technologies has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market.

Summary

Sanuwave Health beats NeuroOne Medical Technologies on 12 of the 16 factors compared between the two stocks.

How does NeuroOne Medical Technologies compare to HeartBeam?

HeartBeam (NASDAQ:BEAT) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

In the previous week, NeuroOne Medical Technologies had 2 more articles in the media than HeartBeam. MarketBeat recorded 11 mentions for NeuroOne Medical Technologies and 9 mentions for HeartBeam. NeuroOne Medical Technologies' average media sentiment score of 0.70 beat HeartBeam's score of 0.10 indicating that NeuroOne Medical Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HeartBeam	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
NeuroOne Medical Technologies	2 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

7.8% of HeartBeam shares are owned by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. 18.0% of HeartBeam shares are owned by insiders. Comparatively, 11.8% of NeuroOne Medical Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

HeartBeam presently has a consensus target price of $4.00, suggesting a potential upside of 732.99%. NeuroOne Medical Technologies has a consensus target price of $7.33, suggesting a potential upside of 554.76%. Given HeartBeam's stronger consensus rating and higher probable upside, equities research analysts plainly believe HeartBeam is more favorable than NeuroOne Medical Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartBeam	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56
NeuroOne Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

HeartBeam has a net margin of 0.00% compared to NeuroOne Medical Technologies' net margin of -71.50%. NeuroOne Medical Technologies' return on equity of -128.12% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartBeam	N/A	-686.78%	-348.65%
NeuroOne Medical Technologies	-71.50%	-128.12%	-86.34%

NeuroOne Medical Technologies has higher revenue and earnings than HeartBeam. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than HeartBeam, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartBeam	N/A	N/A	-$21.01M	-$0.51	N/A
NeuroOne Medical Technologies	$12.10M	0.84	-$3.61M	-$0.95	N/A

HeartBeam has a beta of -0.76, indicating that its stock price is 176% less volatile than the broader market. Comparatively, NeuroOne Medical Technologies has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market.

Summary

HeartBeam and NeuroOne Medical Technologies tied by winning 8 of the 16 factors compared between the two stocks.

How does NeuroOne Medical Technologies compare to Elutia?

NeuroOne Medical Technologies (NASDAQ:NMTC) and Elutia (NASDAQ:ELUT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

NeuroOne Medical Technologies presently has a consensus target price of $7.33, suggesting a potential upside of 554.76%. Given NeuroOne Medical Technologies' stronger consensus rating and higher probable upside, equities research analysts plainly believe NeuroOne Medical Technologies is more favorable than Elutia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroOne Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Elutia	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Elutia has higher revenue and earnings than NeuroOne Medical Technologies. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroOne Medical Technologies	$12.10M	0.84	-$3.61M	-$0.95	N/A
Elutia	$12.29M	2.97	$53.38M	$0.95	0.87

Elutia has a net margin of 426.93% compared to NeuroOne Medical Technologies' net margin of -71.50%. NeuroOne Medical Technologies' return on equity of -128.12% beat Elutia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroOne Medical Technologies	-71.50%	-128.12%	-86.34%
Elutia	426.93%	-407.37%	-47.08%

NeuroOne Medical Technologies has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market. Comparatively, Elutia has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market.

16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. Comparatively, 74.0% of Elutia shares are owned by institutional investors. 11.8% of NeuroOne Medical Technologies shares are owned by insiders. Comparatively, 17.8% of Elutia shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, NeuroOne Medical Technologies had 9 more articles in the media than Elutia. MarketBeat recorded 11 mentions for NeuroOne Medical Technologies and 2 mentions for Elutia. NeuroOne Medical Technologies' average media sentiment score of 0.70 beat Elutia's score of 0.00 indicating that NeuroOne Medical Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroOne Medical Technologies	2 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elutia	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Elutia beats NeuroOne Medical Technologies on 10 of the 16 factors compared between the two stocks.

How does NeuroOne Medical Technologies compare to Accuray?

Accuray (NASDAQ:ARAY) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

64.1% of Accuray shares are held by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are held by institutional investors. 2.4% of Accuray shares are held by company insiders. Comparatively, 11.8% of NeuroOne Medical Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Accuray currently has a consensus target price of $2.00, suggesting a potential upside of 770.70%. NeuroOne Medical Technologies has a consensus target price of $7.33, suggesting a potential upside of 554.76%. Given Accuray's higher probable upside, equities analysts plainly believe Accuray is more favorable than NeuroOne Medical Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Accuray	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
NeuroOne Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Accuray has a beta of 1.42, suggesting that its share price is 42% more volatile than the broader market. Comparatively, NeuroOne Medical Technologies has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market.

Accuray has a net margin of -12.24% compared to NeuroOne Medical Technologies' net margin of -71.50%. Accuray's return on equity of -97.85% beat NeuroOne Medical Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Accuray	-12.24%	-97.85%	-10.82%
NeuroOne Medical Technologies	-71.50%	-128.12%	-86.34%

In the previous week, NeuroOne Medical Technologies had 6 more articles in the media than Accuray. MarketBeat recorded 11 mentions for NeuroOne Medical Technologies and 5 mentions for Accuray. NeuroOne Medical Technologies' average media sentiment score of 0.70 beat Accuray's score of 0.55 indicating that NeuroOne Medical Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Accuray	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NeuroOne Medical Technologies	2 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NeuroOne Medical Technologies has lower revenue, but higher earnings than Accuray. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Accuray, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Accuray	$401.95M	0.07	-$49.19M	-$0.40	N/A
NeuroOne Medical Technologies	$12.10M	0.84	-$3.61M	-$0.95	N/A

Summary

Accuray beats NeuroOne Medical Technologies on 9 of the 16 factors compared between the two stocks.

How does NeuroOne Medical Technologies compare to QT Imaging?

NeuroOne Medical Technologies (NASDAQ:NMTC) and QT Imaging (NASDAQ:QTI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

NeuroOne Medical Technologies has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market. Comparatively, QT Imaging has a beta of 0.02, suggesting that its share price is 98% less volatile than the broader market.

NeuroOne Medical Technologies has a net margin of -71.50% compared to QT Imaging's net margin of -77.25%. NeuroOne Medical Technologies' return on equity of -128.12% beat QT Imaging's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroOne Medical Technologies	-71.50%	-128.12%	-86.34%
QT Imaging	-77.25%	-1,202.69%	-46.76%

NeuroOne Medical Technologies has higher earnings, but lower revenue than QT Imaging. QT Imaging is trading at a lower price-to-earnings ratio than NeuroOne Medical Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroOne Medical Technologies	$12.10M	0.84	-$3.61M	-$0.95	N/A
QT Imaging	$18.92M	1.95	-$21.08M	-$1.57	N/A

NeuroOne Medical Technologies currently has a consensus target price of $7.33, indicating a potential upside of 554.76%. QT Imaging has a consensus target price of $8.00, indicating a potential upside of 198.51%. Given NeuroOne Medical Technologies' stronger consensus rating and higher possible upside, analysts plainly believe NeuroOne Medical Technologies is more favorable than QT Imaging.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroOne Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
QT Imaging	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. Comparatively, 24.2% of QT Imaging shares are owned by institutional investors. 11.8% of NeuroOne Medical Technologies shares are owned by insiders. Comparatively, 25.4% of QT Imaging shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, NeuroOne Medical Technologies had 7 more articles in the media than QT Imaging. MarketBeat recorded 11 mentions for NeuroOne Medical Technologies and 4 mentions for QT Imaging. NeuroOne Medical Technologies' average media sentiment score of 0.70 beat QT Imaging's score of 0.66 indicating that NeuroOne Medical Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroOne Medical Technologies	2 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
QT Imaging	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

NeuroOne Medical Technologies beats QT Imaging on 11 of the 16 factors compared between the two stocks.

Get NeuroOne Medical Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NMTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NMTC vs. The Competition

Export

Metric	NeuroOne Medical Technologies	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.83M	$5.44B	$7.16B	$13.21B
Dividend Yield	N/A	1.78%	2.53%	16.37%
P/E Ratio	-1.18	25.57	274.15	26.16
Price / Sales	0.84	83.25	635.97	113.01
Price / Cash	N/A	31.87	76.38	53.09
Price / Book	1.32	5.93	11.21	6.34
Net Income	-$3.61M	$146.18M	$3.50B	$381.90M
7 Day Performance	N/A	-0.38%	-0.90%	-1.41%
1 Month Performance	-29.11%	-2.02%	-4.44%	-3.48%
1 Year Performance	-80.35%	5.08%	6.96%	1.16%

NeuroOne Medical Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NMTC NeuroOne Medical Technologies	3.4134 of 5 stars	$1.12 +3.7%	$7.33 +554.8%	-81.9%	$9.83M	$12.10M	N/A	18	Short Interest Increase
SNWV Sanuwave Health	1.9487 of 5 stars	$5.20 +10.6%	$47.00 +803.8%	-82.6%	$40.43M	$44.02M	21.67	55	News Coverage
BEAT HeartBeam	2.3534 of 5 stars	$0.58 -10.7%	$4.00 +584.9%	-72.6%	$36.86M	N/A	N/A	1,700	Analyst Forecast
ELUT Elutia	0.802 of 5 stars	$0.78 -5.4%	N/A	-6.7%	$36.39M	$12.29M	0.82	180	Analyst Downgrade
ARAY Accuray	2.2214 of 5 stars	$0.26 -13.3%	$2.00 +664.8%	-87.6%	$36.03M	$401.95M	N/A	809

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NMTC) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NeuroOne Medical Technologies (NMTC) Competitors

NMTC vs. SNWV, BEAT, ELUT, ARAY, and QTI

How does NeuroOne Medical Technologies compare to Sanuwave Health?

Summary

How does NeuroOne Medical Technologies compare to HeartBeam?

Summary

How does NeuroOne Medical Technologies compare to Elutia?

Summary

How does NeuroOne Medical Technologies compare to Accuray?

Summary

How does NeuroOne Medical Technologies compare to QT Imaging?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMTC vs. The Competition

NeuroOne Medical Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NeuroOne Medical Technologies (NMTC) Competitors

NMTC vs. SNWV, BEAT, ELUT, ARAY, and QTI

How does NeuroOne Medical Technologies compare to Sanuwave Health?

Does the media prefer SNWV or NMTC?

Do institutionals and insiders have more ownership in SNWV or NMTC?

Is SNWV or NMTC more profitable?

Do analysts prefer SNWV or NMTC?

Which has preferable earnings and valuation, SNWV or NMTC?

Which has more risk and volatility, SNWV or NMTC?

Summary

How does NeuroOne Medical Technologies compare to HeartBeam?

Does the media favor BEAT or NMTC?

Do institutionals and insiders hold more shares of BEAT or NMTC?

Do analysts prefer BEAT or NMTC?

Is BEAT or NMTC more profitable?

Which has higher earnings and valuation, BEAT or NMTC?

Which has more volatility and risk, BEAT or NMTC?

Summary

How does NeuroOne Medical Technologies compare to Elutia?

Do analysts prefer NMTC or ELUT?

Which has higher valuation & earnings, NMTC or ELUT?

Is NMTC or ELUT more profitable?

Which has more risk & volatility, NMTC or ELUT?

Do institutionals and insiders have more ownership in NMTC or ELUT?

Does the media favor NMTC or ELUT?

Summary

How does NeuroOne Medical Technologies compare to Accuray?

Do institutionals & insiders hold more shares of ARAY or NMTC?

Do analysts prefer ARAY or NMTC?

Which has more volatility and risk, ARAY or NMTC?

Is ARAY or NMTC more profitable?

Does the media favor ARAY or NMTC?

Which has higher earnings & valuation, ARAY or NMTC?

Summary

How does NeuroOne Medical Technologies compare to QT Imaging?

Which has more volatility & risk, NMTC or QTI?

Is NMTC or QTI more profitable?

Which has preferable valuation and earnings, NMTC or QTI?

Do analysts prefer NMTC or QTI?

Do insiders & institutionals have more ownership in NMTC or QTI?

Does the media refer more to NMTC or QTI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMTC vs. The Competition

NeuroOne Medical Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools